జెనెటిక్ ఇంజనీరింగ్ & బయోటెక్నాలజీలో పురోగతి

Omics-Based CHO Cell Engineering – Entrance into Post-Genomic Era

Yeon-Gu Kim

Omics-Based CHO Cell Engineering – Entrance into Post-Genomic Era

Chinese hamster ovary cells (CHO) cells have been the most commonly used mammalian host for the production of therapeutic proteins since the first therapeutic protein from recombinant mammalian cells, tissue plasminogen activator (tPA, Genentech, USA) synthesized in CHO cells, was approved for clinical use in 1987. Despite the availability of various mammalian cell lines (such as BHK, HEK-293, HeLa, NS0, and PerC6), nearly 70% of all recombinant protein therapeutics produced today are made in CHO cells.